-
Microneedle Delivery of Risedronate for Osteoporosis
2026-09-27
A 2023 formulation study combined Risedronate Sodium and ursolic acid in nanotransfersomes and incorporated them into a dissolving gelatin microneedle patch. The optimized system showed sustained in vitro release and substantial ex vivo skin permeation, supporting further evaluation of transdermal delivery—not yet demonstrating clinical or in vivo osteoporosis efficacy.
-
Camptothecin Workflows for DNA Damage Research
2026-09-26
Use Camptothecin to connect topoisomerase I inhibition with DNA-damage signaling, cell fate, and autophagy in cancer models. This practical guide pairs a dose-bracketing workflow with clear limits on what a recent yeast adaptation study can—and cannot—tell you about mammalian-cell experiments.
-
Cy5 Hydrazide for Carbonyl Labeling in Viability Studies
2026-09-25
Learn how Cy5 hydrazide (non-sulfonated), SKU A8145, can complement cell viability and cytotoxicity assays by labeling carbonyl-containing biomolecules. This practical guide covers assay boundaries, spectral properties, preparation, interpretation, and product selection.
-
Tricine-SDS-PAGE Gel Preparation Kit Guide
2026-09-25
The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is designed to improve separation of small proteins and peptides, including targets that may be poorly resolved by conventional Tris-SDS-PAGE. It is intended for scientific research workflows, not diagnostic or medical use.
-
Prion Self-Assembly Tunes Mutagenesis for Rapid Adaptation
2026-09-24
A 2026 Cell study reports that prion-like self-assembly of DNA repair and recombination proteins can act as a heritable, reversible switch that reshapes mutagenesis and adaptive outcomes. Its findings connect protein-state inheritance with rapid stress adaptation in yeast and the emergence of fluconazole resistance in Candida albicans, while highlighting important limits on translating experimental evolution results into clinical strategies.
-
Imatinib (STI571) in Gastric Cancer Assembloid Research
2026-09-24
Imatinib (STI571) inhibits Abl, PDGF receptor, and c-Kit kinase activity, making it a useful tool for testing kinase-dependent signaling. Patient-derived gastric cancer assembloids provide a way to ask whether matched stromal cells modify responses to this inhibitor, but the assembloid study did not test Imatinib.
-
BoNT/A Suppresses Ocular Angiogenesis Through SOCS3
2026-09-24
A laser-induced choroidal neovascularization study found that intravitreal botulinum neurotoxin serotype A (BoNT/A) reduced lesion size and vascular leakage while suppressing retinal glial activation. The results implicate neuronal/glial SOCS3 in this protective response and offer a mechanistic direction for studying pathological retinal angiogenesis beyond VEGF alone.
-
Gap26: Translating Connexin 43 Signaling
2026-09-23
A thought-leadership guide to using Gap26 as a mechanistic probe of connexin 43 communication, with strategic lessons from spinal astrocyte research in breakthrough cancer pain.
-
SIRT1/2 Inhibitor IV (cambinol) Workflows
2026-09-22
This scenario-based guide explains how SIRT1/2 Inhibitor IV (cambinol), SKU B6063, can support controlled studies of viability, p53 acetylation, apoptosis, lactylation, and tumor biology. It separates product-supported evidence from practical optimization recommendations to help laboratories improve assay interpretation and reproducibility.
-
Camptothecin at the Adaptive DNA Damage Frontier
2026-09-22
Camptothecin is more than a topoisomerase I inhibitor: it is a controllable probe for DNA damage signaling, cellular fate, autophagy, and adaptive genome behavior. This thought-leadership framework connects established cancer biology workflows with emerging evidence that heritable protein states can reshape mutagenesis under selective pressure.
-
MMP7–β-Catenin Signaling in Biliary Atresia Fibrosis
2026-09-21
A 2026 study identifies MMP7 as a mechanistic driver of epithelial–mesenchymal transition and liver fibrosis in biliary atresia, linking E-cadherin cleavage to β-catenin nuclear translocation. Its combination of patient samples, transcriptomic analysis, cell experiments, and a chronic mouse model supports MMP7 and the E-cadherin/β-catenin axis as testable antifibrotic targets.
-
Forskolin Workflows for Pancreatic Organoids
2026-09-21
Use Forskolin as a controlled adenylate cyclase activator to test how cAMP modulation affects pancreatic ductal organoid initiation, composition, and stability. This practical guide connects organoid optimization with stem-cell, neuroendocrine, inflammatory, and cardiovascular disease research while separating reference-backed findings from assay starting points.
-
Cy5 Goat Anti-Rabbit IgG (H+L) Antibody Workflow
2026-09-20
Translate rabbit-primary immunoassays into sensitive far-red readouts for MAVS, ASB3, and antiviral signaling studies. This workflow combines practical fluorescence optimization with controls that prevent signal amplification from being mistaken for mechanistic proof.
-
Bufalin Targets STK33 in Triple-Negative Breast Cancer
2026-09-19
A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding partner and degradation target of Bufalin in triple-negative breast cancer. By combining target-discovery assays, mechanistic studies, animal models, and patient-derived organoids, the work connects STK33 loss to reduced tumor growth and provides a framework for evaluating Bufalin as a chemical probe in TNBC research.
-
Dicloxacillin Activity Against Intracellular S. aureus
2026-09-19
The reference study integrated THP-1 macrophage experiments with a murine peritonitis model to compare dicloxacillin activity against extracellular and intracellular Staphylococcus aureus. Its key translational finding was that free-drug time above the MIC, rather than peak concentration or total exposure alone, best predicted efficacy in both compartments.